Technical Analysis for EYPT - EyePoint Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 1.7 -0.58% -0.01
EYPT closed down 0.58 percent on Friday, January 17, 2020, on 74 percent of normal volume.
Earnings due: Feb 5
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical EYPT trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 200 DMA Bullish -0.58%
Expansion Breakout Bullish Swing Setup -0.58%
Pocket Pivot Bullish Swing Setup -0.58%
Wide Range Bar Range Expansion -0.58%
Upper Bollinger Band Walk Strength -0.58%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Medicine Chemistry Biopharmaceutical Organic Compounds Technology Platforms Wet Age Related Macular Degeneration Glucocorticoids Macular Edema Ophthalmic Products Uveitis Chronic Diseases Diabetic Macular Edema Eye Diseases Pregnanes Alimera Sciences Cytomegalovirus Retinitis Diketones Diols

Is EYPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.82
52 Week Low 1.19
Average Volume 573,002
200-Day Moving Average 1.66
50-Day Moving Average 1.51
20-Day Moving Average 1.53
10-Day Moving Average 1.56
Average True Range 0.10
ADX 20.12
+DI 32.42
-DI 9.89
Chandelier Exit (Long, 3 ATRs ) 1.53
Chandelier Exit (Short, 3 ATRs ) 1.71
Upper Bollinger Band 1.68
Lower Bollinger Band 1.38
Percent B (%b) 1.08
BandWidth 19.41
MACD Line 0.03
MACD Signal Line 0.00
MACD Histogram 0.0299
Fundamentals Value
Market Cap 66.93 Million
Num Shares 39.4 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -3.27
Price-to-Sales 6.21
Price-to-Book 3.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.88
Resistance 3 (R3) 1.89 1.84 1.85
Resistance 2 (R2) 1.84 1.80 1.84 1.84
Resistance 1 (R1) 1.77 1.77 1.75 1.76 1.83
Pivot Point 1.72 1.72 1.71 1.72 1.72
Support 1 (S1) 1.65 1.68 1.63 1.64 1.57
Support 2 (S2) 1.60 1.65 1.60 1.56
Support 3 (S3) 1.53 1.60 1.55
Support 4 (S4) 1.52